Bayh-Dole Act
A 1980 US law allowing universities, medical schools, and NIH-funded researchers to patent discoveries made with public funding and license them exclusively to private companies in return for royalties.
As defined in Marcia Angell on Big Pharma
Where it comes up · 2
- Marcia Angell on Big Pharma3 claims
- The Venture Capitalist Who Bets on Science Most Investors Think Is Impossible | Josh Wolfe1 claim
Most important claims · 4 of 4Search all claims for “Bayh-Dole Act” →
- The 1980 Bayh-Dole Act allowing universities and principal investigators to own IP from government-funded research was transformational; it enabled venture capital to commercialize academic research and, combined with ERISA allowing pension funds into VC, created the modern VC ecosystem.The Venture Capitalist Who Bets on Science Most Investors Think Is Impossible | Josh Wolfe
- Since the 1980 Bayh-Dole Act let universities and the NIH patent publicly funded discoveries and license them exclusively to big drug companies for royalties, pharmaceutical firms no longer need to do their own innovative basic research and instead license or buy early discoveries, leaving them only the expensive but non-innovative late-stage clinical development.Marcia Angell on Big Pharma
- Around 1981 the courts relaxed patent criteria so that 'practical use'—which previously required a use at the bedside—was redefined to mean a use in further research, lowering the bar for obtaining drug patents alongside the Bayh-Dole changes.Marcia Angell on Big Pharma
- Companies should still pay for research on their own drugs but the money should flow through an independent NIH institute that commissions trials from academic centers, so that study design is not controlled by the companies, and medical schools and physicians should be taken off drug-company payrolls.Marcia Angell on Big Pharma